ender diagnostics and SWISS collaborate to test cabin crew for COVID-19
7.9.2020 09:00:00 EEST | Business Wire | Press release
ender diagnostics, a Swiss company specializing in the development of rapid molecular biological tests, today announced a collaboration with Swiss International Air Lines (SWISS), a subsidiary of Lufthansa AG, to test all long-haul cabin crew members for SARS-CoV-2, the virus which causes COVID-19.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200906005019/en/
Swiss Airlines COVID-19 Test Center (Photo: Business Wire)
Constant rapid and flexible testing is the key to controlling the coronavirus pandemic. Testing SWISS long-haul crew members prior to departure working with ender diagnostics will help to further improve detection of COVID-19 infection, increasing the safety and confidence of people traveling.
Martin Knuchel, Head of Crisis, Emergency & Business Continuity Management Lufthansa Group Airlines and Pandemic Coordinator, commented: «The safety and confidence of our passengers and employees is paramount for SWISS. The decision to adopt the fast, innovative and easy-to-use testing solutions developed by ender diagnostics further underlines our absolute commitment to make air travel as safe as possible.»
ender diagnostics specializes in isothermal PCR*-based test kits for laboratory and on-site diagnosis. It has launched two CE-marked tests in Europe: ender LAB in June and ender MASS in August 2020. The ender LAB test allows laboratories to directly detect SARS-CoV-2 on standard real-time PCR devices within 30 minutes of extraction of the viral RNA. This is significantly faster than commercially available PCR tests, which take several hours. ender MASS offers additional benefits by enabling detection in a simplified process, considerably reducing the workload for medical professionals and laboratories. It is designed to enable on-site and pop-up labs to operate rapid testing in diverse settings, including travel-related locations such as airports and cruise ships.
Hans-Peter Frank, Chief Business Officer of ender diagnostics, said: «With simplified workflows and analysis, our products can process up to eight times as many tests as conventional PCR test over the same period. This significantly increases both test capacity and flexibility in laboratories and is a promising step towards mass screening. We are pleased to be able to support SWISS in their efforts to protect their passengers and employees.»
About ender diagnostics
ender diagnostics is a private company headquartered in Bern, Switzerland, and with US offices in Miami. ender diagnostics focuses on the development of rapid molecular tests for the detection of SARS-CoV-2. The ender team has extensive experience in developing molecular biological rapid tests for infectious diseases. The company is supported by several private investors with know-how and financing. https://enderdiagnostics.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200906005019/en/
Contact information
For media inquiries, please contact:
media@enderdiagnostics.com
For more information about ender diagnostics’ products, please contact:
info@enderdiagnostics.com
Hans-Peter Frank
Chief Business Officer
hp.frank@enderdiagnostics.com
+41 79 743 27 77
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 11:22:00 EET | Press release
Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh
Incyte Announces the European Commission Approval of Zynyz ® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 23:42:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meury, President and Chief Executive Officer, Incyte. “As the first PD-1 immunotherapy approved in Europe in combination with platinum-based chemotherapy in the first-line setting, Zynyz helps expand the standard-of-care options available to clinicians and underscores our commitment to delivering innovative medicines that can have an impact for patients.” The EC decision follows the January 2026 positive opinion received from the European Medicines Agency’s Committee f
Dfns Launches Payouts6.3.2026 22:27:00 EET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 21:23:00 EET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 19:30:00 EET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom